Borealis Biosciences

Executive Summary

Borealis Biosciences is a synthetic biology company engineering live bacterial therapeutics to treat metabolic and inflammatory diseases. Founded in 2020 and headquartered in Boston, the company has raised $150 million to date. Its platform leverages genetically modified microbes that colonize the gut and perform precise therapeutic functions, such as producing beneficial metabolites or degrading harmful compounds. This approach aims to harness the microbiome for localized drug delivery, potentially reducing systemic side effects and improving efficacy. Borealis is currently in the preclinical stage, focusing on advancing its lead programs toward Investigational New Drug (IND) applications. The company's technology targets two large and growing markets: metabolic disorders (e.g., obesity, diabetes) and gastrointestinal inflammatory conditions (e.g., inflammatory bowel disease). With significant funding and a novel platform, Borealis is positioned to address unmet needs in these areas, though it remains early-stage and unprofitable. Investor attention will focus on the company's ability to demonstrate proof-of-concept in vivo and progress toward clinical trials.

Upcoming Catalysts (preview)

• Q4 2026IND filing for lead metabolic program45% success
• H2 2026New series C funding round70% success
• Q3 2026Publication of preclinical efficacy data in a top-tier journal60% success